Lipoprotein(a), Chlamydia pneumoniae, leptin and tissue plasminogen activator as risk markers for valvular aortic stenosis

European Heart Journal

Volumn 24, Issue 2, 2003, Pages 198-208

  Glader, Christine Ahlbeck ^a   Birgander, L S ^b   Soderberg S ^b   Ildgruben, H P ^b   Saikku, P ^b   Waldenstrom A ^b   Dahlen G H ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

Chlamydia pneumoniae; Circulating immune complexes; Leptin; Lipoprotein(a); Tissue plasminogen activator; Valvular aortic stenosis

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; LEPTIN; LIPOPROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGE; AGED; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; AORTA VALVE REPLACEMENT; AORTA VALVE STENOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CHLAMYDOPHILA PNEUMONIAE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; ECHOCARDIOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SYMPTOMATOLOGY;

AGED; AORTIC VALVE STENOSIS; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LEPTIN; LIPOPROTEIN(A); MALE; REGRESSION ANALYSIS; RISK FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0037260393     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-668X(02)00385-8     Document Type: Article

References (74)

1. Otto CM, Kuusisto J, Reichenbach DD et al. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994;90:844-53.
2. O'Brien KD, Reichenbach DD, Marcovina SM et al. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996;16:523-32.
3. Olsson M, Dalsgaard CJ, Haegerstrand A et al. Accumulation of T lymphocytes and expression of interleukin-2 receptors in nonrheumatic stenotic aortic valves. J Am Coll Cardiol 1994;23:1162-70.
4. Dahlén GH, Ericson C, Furberg C et al. Studies on an extra pre-beta lipoprotein fraction. Acta Med Scand Suppl 1972; 531:1-29.
5. Dahlén GH. Lipoprotein (a) as a risk factor for atherosclerotic diseases. Arctic Med Res 1988;47(Suppl 1):458-61.
6. Rhoads GG, Dahlén GH, Berg K et al. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA 1986; 256:2540-4.
7. Kostner GM, Avogaro P, Cazzolato G et al. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis 1981; 38:51-61.
8. Dahlén GH, Guyton JR, Attar M et al. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986;74:758-65.
9. Saikku P, Leinonen M, Mattila K et al. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988;2:983-6.
10. Dahlén GH. Indications of an autoimmune component in Lp(a) associated disorders. Eur J Immunogenet 1994; 21:301-12.
11. Glader CA, Boman J, Saikku P et al. The proatherogenic properties of lipoprotein(a) may be enhanced through the formation of circulating immune complexes containing Chlamydia pneumoniae-specific IgG antibodies. Eur Heart J 2000;21:639-46.
12. Söderberg S, Ahren B, Jansson JH et al. Leptin is associated with increased risk of myocardial infarction. J Intern Med 1999;246:409-18.
13. Söderberg S, Ahren B, Stegmayr B et al. Leptin is a risk marker for first-ever hemorrhagic stroke in a populationbased cohort. Stroke 1999;30:328-37.
14. Fruhbeck G. Pivotal role of nitric oxide in the control of blood pressure after leptin administration. Diabetes 1999; 48:903-8.
15. Lord GM, Matarese G, Howard JK et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature 1998;394:897-901.
16. Juhan-Vague I, Pyke SDM, Alessi MC et al. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. Circulation 1996; 94:2057-63.
17. Thompson SG, Kienast J, Pyke SD et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995;332:635-41.
18. Thögersen AM, Jansson JH, Boman K et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both man and women; evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998; 98:2241-7.
19. Skjaerpe T, Hegrenaes L, Hatle L. Noninvasive estimation of valve area in patients with aortic stenosis by Doppler ultrasound and two-dimensional echocardiography. Circulation 1985;72:810-8.
20. Linnanmäki E, Leinonen M, Mattila K et al. Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation 1993;87:1130-4.
21. Wang SP, Grayston JT. Microimmunofluorescense serological studies with the TWAR organism. In: Oriel JD, Ridgeway G, Schachter J, Taylor-Robinson D, Ward M, editors. Chlamydial infections. Cambridge: Cambridge University Press; 1986, p. 329-32.
22. Rothman KJ. Interactions between causes. Modern epidemiology. Boston: Little, Brown; 1986, p. 315-20.
23. Hallqvist J, Ahlbom A, Diderichsen F et al. How to evaluate interaction between causes: a review of practices in cardiovascular epidemiology. J Intern Med 1996;239:377-82.
24. Sahasakul Y, Edwards WD, Naessens JM et al. Age-related changes in aortic and mitral valve thickness: implications for two-dimensional echocardiography based on an autopsy study of 200 normal human hearts. Am J Cardiol 1988; 62:424-30.
25. Beppu S, Suzuki S, Matsuda H et al. Rapidity of progression of aortic stenosis in patients with congenital bicuspid aortic valves. Am J Cardiol 1993;71:322-7.
26. Fenoglio JJ, McAllister HA, Decastro CM et al. Congenital bicuspid aortic valve after age 20. Am J Cardiol 1977; 39:164-9.
27. Subramanian R, Olson LJ, Edwards WD. Surgical pathology of pure aortic stenosis: a study of 374 cases. Mayo Clin Proc 1984;59:683-90.
28. Mautner GC, Roberts WC. Reported frequency of coronary arterial narrowing by angiogram in patients with valvular aortic stenosis. Am J Cardiol 1992;70:539-40.
29. Aronow WS, Ahn C, Shirani J et al. Comparison of frequency of new coronary events in older persons with mild, moderate, and severe valvular aortic stenosis with those without aortic stenosis. Am J Cardiol 1998;81:647-9.
30. Aronow WS, Ahn C, Shirani J et al. Comparison of frequency of new coronary events in older subjects with and without valvular aortic sclerosis. Am J Cardiol 1999;83:599-600. [A8].
31. Chobadi R, Wurzel M, Teplitsky I et al. Coronary artery disease in patients 35 years of age or older with valvular aortic stenosis. Am J Cardiol 1989;64:811-2.
32. Mohler ER, Sheridan MJ, Nichols R et al. Development and progression of aortic valve stenosis: atherosclerosis risk factors-a causal relationship? A clinical morphologic study. Clin Cardiol 1991;14:995-9.
33. Stewart BF, Siscovick D, Lind BK et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997;29:630-4.
34. Palta S, Pai AM, Gill KS et al. New insights into the progression of aortic stenosis. Circulation 2000;101:2497-502.
35. Aronow WS, Schwartz KS, Koenigsberg M. Correlation of serum lipids, calcium, and phosphorus, diabetes mellitus and history of systemic hypertension with presence or absence of calcified or thickened aortic cusps or root in elderly patients. Am J Cardiol 1987;59:998-9.
36. Boon A, Cheriex E, Lodder J et al. Cardiac valve calcification: characteristics of patients with calcification of the mitral annulus or aortic valve. Heart 1997;78:472-4.
37. Wilmshurst PT, Stevenson RN, Griffiths H et al. A casecontrol investigation of the relation between hyperlipidaemia and calcific aortic valve stenosis. Heart 1997;78:475-9.
38. Novaro GM, Pearce GL, Sprecher DL et al. Comparison of cardiovascular risk and lipid profiles in patients undergoing aortic valve surgery versus those undergoing coronary artery bypass grafting. J Heart Valve Dis 2001;10:19-24.
39. Lindroos M, Kupari M, Valvanne J et al. Factors associated with calcific aortic valve degeneration in the elderly. Eur Heart J 1994;15:865-70.
40. Gotoh T, Kuroda T, Yamasawa M et al. Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). Am J Cardiol 1995;76:928-32.
41. McLean JW, Tomlinson JE, Kuang WJ et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987;330:132-7.
42. Jansson JH, Nilsson TK, Olofsson BO. Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris. Eur Heart J 1991;12:157-61.
43. Söderberg S, Jansson JH, Ahren B et al. Leptin, tPA and Lp(a) are associated with increased risk of myocardial infarction. Circulation 2000;100(Suppl 18):3914.
44. Nyström RC, Thelin S, Hjelm E et al. High incidence of Chlamydia pneumoniae in sclerotic heart valves of patients undergoing aortic valve replacement. Scand J Infect Dis 1997;29:361-5.
45. Juvonen J, Laurila A, Juvonen T et al. Detection of Chlamydia pneumoniae in human nonrheumatic stenotic aortic valves. J Am Coll Cardiol 1997;29:1054-9.
46. Juvonen J, Juvonen T, Laurila A et al. Can degenerative aortic valve stenosis be related to persistent Chlamydia pneumoniae infection?. Ann Intern Med 1998;128:741-4.
47. Andreasen JJ, Farholt S, Jensen JS. Failure to detect Chlamydia pneumoniae in calcific and degenerative arteriosclerotic aortic valves excised during open heart surgery. APMIS 1998;106:717-20.
48. Apfalter P, Blasi F, Boman J et al. Multicenter comparison trial of DNA extraction methods and PCR assays for detection of Chlamydia pneumoniae in endarterectomy specimens. J Clin Microbiol 2001;39:519-24.
49. Wang SP. The microimmunofliuorescence test for Chlamydia penumoniae infection: Technique and interpretation. J Infect Dis 2000;181(Suppl 3):421-5.
50. Siscovick DS, Schwartz SM, Caps M et al. Chlamydia pneumoniae and atherosclerotic risk in populations: the role of seroepidemiology. J Infect Dis 2000;181(Suppl 3):417-20.
51. Campbell LA, O'Brien ER, Cappuccio AL et al. Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues. J Infect Dis 1995;172:585-8.
52. Puolakkainen M, Kuo CC, Shor A et al. Serological response to Chlamydia pneumoniae in adults with coronary arterial fatty streaks and fibrolipid plaques. J Clin Microbiol 1993; 31:2212-4.
53. Juvonen J, Juvonen T, Laurila A et al. Demonstration of Chlamydia pneumoniae in the walls of abdominal aortic aneurysms. J Vasc Surg 1997;25:499-505.
54. Boman J, Söderberg S, Forsberg J et al. High prevalence of Chlamydia pneumoniae DNA in peripheral blood mononuclear cells in patients with cardiovascular disease and in middle-aged blood donors. J Infect Dis 1998; 178:274-7.
55. Dahlén GH, Boman J, Birgander LS et al. Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease. Atherosclerosis 1995;114:165-74.
56. Dahlén GH, Slunga L, Holmlund G et al. Lp(a) lipoprotein and HLA-DR genotype in early coronary artery disease. Eur J Immunogenet 1993;20:95-102.
57. Kuo CC, Gown AM, Benditt EP et al. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb 1993;13:1501-4.
58. Kaukoranta TSS, Teppo AM, Laitinen K et al. Growth of Chlamydia pneumoniae in cultured human peripheral blood mononuclear cells and induction of a cytokine response. Microb Pathog 1996;215-21.
59. Gianturco SH, Bradley WA, Dahlén GH et al. Interaction of tipoprotein(a) with murine peritoneal macrophages and cultured human fibroblasts. [Abstr]. Arteriosclerosis 1983; 3:500A.
60. Dahlén GH, Stentund H. Lp(a) tipoprotein is a major risk factor for cardiovascular disease: pathogenic mechanisms and clinical significance. Clin Genet 1997;52:272-80.
61. Füst G. Studies on the occurrence of circulating immune complexes in vascular diseases. Atherosclerosis 1978; 29:181-90.
62. Maisch B, Mayer E, Schubert U et al. Immune reactions in infective endocarditis. II. Relevance of circulating immune complexes, serum inhibition factors, tymphocytotoxic reactions, and antibody-dependent cellular cytotoxicity against cardiac target cells. Am Heart J 1983;106:338-44.
63. Gallagher PJ, Jones DB, Casey CR et al. Circulating immune complexes in cardiac disease. Atherosclerosis 1982; 44:245-60.
64. Cristea A, Rus H, Niculescu F et al. Characterization of circulating immune complexes in heart disease. Immunol Lett 1986;13:45-9.
65. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.
66. Ruige JB, Dekker JM, Blum WF et al. Leptin and variables of body adiposity, energy balance, and insulin resistance in a population-based study. The Hoorn Study. Diabetes Care 1999;22-1097-104.
67. Mallamaci F, Cuzzola F, Tripepi G et al. Gender-dependent differences in plasma leptin in essential hypertension. Am J Hypertens 2000;13:914-20.
68. Rainwater DL, Comuzzie AG, VandeBerg JL et al. Serum leptin levels are independently correlated with two measures of HDL. Atherosclerosis 1997;132:237-43.
69. Söderberg S, Otsson T, Eliasson M et al. Plasma leptin levels are associated with abnormal fibrinolysis in men and postmenopausal women. J Intern Med 1999;245:533-43.
70. Nakata M, Yada T, Soejima N et al. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 1999;48:426-9.
71. Haynes WG, Sivitz WI, Morgan DA et al. Sympathetic and cardiorenal actions of leptin. Hypertension 1997;30:619-23.
72. Zhang F, Basinski MB, Beals JM et al. Crystal structure of the obese protein leptin-E100. Nature 1997;387:206-9.
73. Hiroike T, Higo J, Jingami H et al. Homology modeling of human leptin/leptin receptor complex. Biochem Biophys Res Commun 2000;275:154-8.
74. Gainsford T, Willson TA, Metcalf D, et al. Leptin can induce proliferation, differentiation, and functional activation of hemopoietic cells. Proc Natl Acad Sci USA 1996; 93:14564-8.